School of Nursing, Fudan University, Shanghai, 200032, China.
Youjiang Medical University for Nationalities, Baise, 533000, China.
J Bone Miner Metab. 2019 Jul;37(4):722-728. doi: 10.1007/s00774-018-0974-4. Epub 2018 Nov 21.
Re-fracture risk is higher following osteoporotic fracture. However, there is no accurately reported rate of re-fracture incidence in southwest China. The purpose of this study was to describe the osteoporotic vertebral fracture (OVF) survival for re-fracture state and analyze the risk of re-fracture. This historical cohort study was conducted in four hospitals in southwest China. Patients aged ≥ 50 years (n = 586) with OVF who were supposed to receive anti-osteoporosis drugs after the fracture were included (2012-2017). Telephone follow-up and referring case files were used to estimate the survival for re-fracture and identify the determinants of re-fracture. A total of 555 patients completed the follow-up investigation. Overall, 285 patients experienced a re-fracture, and the longest follow-up investigation time was 72 months. The survival rates for re-fracture at 12 months, 24 months, 36 months, and 48 months were 82.0%, 71.5%, 61.7%, and 34.0%, respectively. The factors correlated with re-fracture hazard were advanced age [hazard ratio (HR) = 1.996], being female (HR = 1.342), smoking (HR = 1.435), history of hypertension (HR = 1.219) and diabetes (HR = 3.271), and persistence of taking anti-osteoporosis drugs after fracture [0-3 months, 4-6 months, 7-12 months, and more than 12 months (HR = 0.703)]. OVF patients with advanced age, who were female, smoked, had fracture with hypertension or diabetes, and who complied poorly with anti-osteoporosis drug treatment presented higher prevalence of re-fracture and low anti-osteoporosis adherence in southwest China. The management of anti-osteoporosis after fracture is necessary in this area.
再次骨折风险在骨质疏松性骨折后较高。然而,中国西南部并没有准确报告再骨折发生率的报告。本研究的目的是描述骨质疏松性椎体骨折(OVF)的再骨折状态生存,并分析再骨折的风险。这是一项在中国西南部的 4 家医院进行的历史性队列研究。纳入了年龄≥50 岁(n=586)、骨折后拟接受抗骨质疏松药物治疗的 OVF 患者(2012-2017 年)。通过电话随访和查阅病历来估计再骨折的生存情况,并确定再骨折的决定因素。共有 555 例患者完成了随访调查。总体而言,285 例患者发生了再骨折,最长随访时间为 72 个月。12 个月、24 个月、36 个月和 48 个月的再骨折生存率分别为 82.0%、71.5%、61.7%和 34.0%。与再骨折风险相关的因素包括年龄较大(风险比[HR] = 1.996)、女性(HR = 1.342)、吸烟(HR = 1.435)、高血压病史(HR = 1.219)和糖尿病(HR = 3.271),以及骨折后持续服用抗骨质疏松药物(0-3 个月、4-6 个月、7-12 个月和>12 个月[HR = 0.703])。中国西南部 OVF 患者年龄较大、女性、吸烟、合并高血压或糖尿病,以及抗骨质疏松药物治疗依从性差,其再骨折发生率较高,抗骨质疏松药物治疗依从性较低。在该地区,骨折后抗骨质疏松药物的管理是必要的。